Category: News & Events

Heart Failure with Preserved Ejection Fraction: Important Things to Know About the Stiff Heart

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Heart failure remains a leading cause of morbidity, mortality, and healthcare expenditure, both nationally and worldwide. In the current era of cardiovascular disease, heart failure with preserved ejection fraction (HFpEF) is recognized to be a clinical entity with equal prevalence and similar morbidity and mortality rates to the traditional syndrome of heart failure with reduced ejection fraction (HFrEF), yet with distinct differences. The HFpEF phenotype presents many challenges, beginning with accurate diagnosis, because the differential diagnosis for patients with symptoms of dyspnea in the context of a normal ejection fraction remains very broad. Moreover, although numerous medical and device-based therapies have been identified in the past several decades to improve clinical outcomes in HFrEF, treatment options for HFpEF with similar efficacy are lacking. Familiarity with the current understanding of the underlying pathophysiology of HFpEF can aid in overcoming some of these challenges, although the mechanisms resulting in HFpEF and the proper therapies remain incompletely defined.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0058

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Juan R. Vilaro. Heart Failure with Preserved Ejection Fraction: Important Things to Know About the Stiff Heart. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0058

Loading

Robotic Percutaneous Coronary Intervention in Coronary Heart Disease: Applications and Recent Advances

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  Traditional percutaneous coronary intervention (T-PCI) has long been an effective method for treating coronary heart disease (CHD), but the radiation hazards and orthopedic injuries among T-PCI operators are concerning. These problems have been mitigated with the emergence of robotic percutaneous coronary intervention (R-PCI), which is expected to increase intervention accuracy and safety. In this review, the current status of PCI development is summarized, including robot systems, and PCI application and evaluation. T-PCI and R-PCI are compared to identify the benefits for patients and physicians. In addition, a new R-PCI system is described, R-PCI WSER-CD01, which incorporates multi-instrument collaborative delivery and provides full-process assistance in minimally invasive vascular intervention. This system introduces three key innovations that address safety concerns, and improve the accuracy, wire compatibility, and remote operation capabilities of existing of vascular intervention robot systems. Finally, prospects for the development of R-PCI are discussed. As an emerging technology, R-PCI aligns well with the trends of precision medicine and telemedicine, and therefore warrants continued innovation.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0062

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Yan-Jun Song, Zechen Liu and Weihua Song et al. Robotic Percutaneous Coronary Intervention in Coronary Heart Disease: Applications and Recent Advances. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0062

Loading

Expert Consensus on ECG Identification Applied in the Insurance Industry

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  Electrocardiograms (ECGs) have the potential to be used as a reliable source of information for human identity recognition due to their universality, portability, and unique and stable biological identification features. This method enriches and refines existing biometric identification techniques, and is suitable for customer identity identification in the insurance industry. This article:

  • Introduces biometric identification techniques commonly used in the insurance industry, including ECG biometric identification techniques, and their advantages;
  • Discusses major aspects of ECG biometric identification techniques;
  • Systematically reviews the most recent advances in ECG identification and extraction characteristics from research in China and other countries;
  • Outlines the technical aspects of using ECGs for recognizing client identity in the insurance industry;
  • And discusses the future of ECGs in identity recognition.

This article is aimed at further promoting the application of living personal ECG identification techniques in the insurance industry, and extending it to areas including medical insurance, banking, justice, public security, military, government, enterprises, and other departments and areas in which identification is needed to promote social stability and national security.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0061

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Zhongjian Li, Kangyin Chen and Shifeng Li et al. Expert Consensus on ECG Identification Applied in the Insurance Industry. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0061

Loading

HNP-1 Reverses Hypertensive Left Ventricular Hypertrophy by Inhibiting the NF-кB Signaling Pathway

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  Human neutrophil peptide-1 (HNP-1) is a commonly investigated therapeutic agent. However, its role in hypertensive left ventricular hypertrophy (HLVH) remains unclear.

HNP-1 levels were measured in patients with hypertension and treated HLVH rat and H9c2 cell hypertrophy models with HNP-1. Cardiomyocyte hypertrophy indexes (i.e., single-cell surface area, left ventricular fibrosis area, BNP levels, and β-MHC levels) were measured with hematoxylin-eosin and Masson’s trichrome staining and WB. NF-кB signaling factors (i.e., IKKβ, p-IKKβ, IкBα, p-IкBα, p65, and p-p65) were measured with WB and qPCR. Finally, inflammatory factors (i.e., IL-6, IL-1α, and TNF-α) were measured with ELISA.

HNP-1 levels were lower in the exposure than the control groups (M (95% CI), 48.83 (45.64–52.26) vs. 59.03 (55.62–62.54), P = 0.000). Diminished HNP-1 was associated with HLVH occurrence in patients. HLVH rat and H9c2 cell hypertrophy models revealed elevated cardiomyocyte hypertrophy indexes and NF-кB signaling and inflammatory factors. However, each HNP-1 treatment group showed lower levels of the aforementioned indices than were observed in the model groups.

Diminished HNP-1 is a risk factor for HLVH. HNP-1 treatment may reverse HLVH by inhibiting NF-кB signaling pathways.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0057

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Xiaorong Duan and Zhenqiu Yu. HNP-1 Reverses Hypertensive Left Ventricular Hypertrophy by Inhibiting the NF-кB Signaling Pathway. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0057

Loading

Alive Without a Pulse: Evolution of Durable Left Ventricular Assist Devices

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  Durable left ventricular assist devices (LVADs) offer a viable option for patients with advanced heart failure and have been demonstrated to be superior to optimal medical therapy in terms of both mortality and quality of life, in selected patients. However, durable LVADs can be associated with severe morbidity. Because the rates of cardiac transplantation are limited by supply, understanding of the evolution of durable LVAD support is necessary to drive innovations to optimize outcomes. The authors of this article review progress in durable LVAD support in contemporary practice and propose future directions requiring additional study.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0056

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Eric Czinn, Anas Jawaid and Leway Chen. Alive Without a Pulse: Evolution of Durable Left Ventricular Assist Devices. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0056

Loading

Top Ten Breakthroughs in Clinical Hypertension Research in 2022

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  Hypertension is a major global public health concern whose disease burden affects an estimated 1.4 billion people worldwide and is associated with 10.8 million deaths annually. Despite substantial advances in medical care, the prevalence of hypertension has markedly increased, owing to population aging; poor treatment adherence; and increases in risk factors, such as excessive salt intake, and overweight and obesity. Consequently, the disability-adjusted life years have increased by 40%, primarily because of elevated risk of stroke, coronary atherosclerosis, heart failure, and kidney failure. Major outstanding problems associated with the treatment and management of hypertension include determining optimal blood pressure targets, developing innovative antihypertensive medications and devices, and implementing effective and feasible hypertension management strategies. To address these challenges, numerous clinical trials are currently underway.

This article highlights the most influential ten clinical studies on hypertension in 2022. The rational use of antihypertensive medications is concluded to be important for effective hypertension management. Important considerations include medication types and dosing times; optimal blood pressure targets; the development of new drugs and therapeutic devices; specific community characteristics, such as village doctor-led care; and healthful diets.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0054

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Qiaoxi Yang and Jun Cai. Top Ten Breakthroughs in Clinical Hypertension Research in 2022. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0054

Loading

Multimodality Imaging for Cardiomyopathies in the Era of Precision Medicine

Announcing a new publication for Cardiovascular Innovations and Applications journal.   A clinical approach to new cardiomyopathy entails defining patient phenotype and disease pathophysiology. After echocardiography, invasive assessments to define hemodynamics and coronary anatomy are usually pursued. In selected non-ischemic cases, endomyocardial biopsies are performed in search for an etiology. Fortunately, advances in cardiac imaging allow for a multifaceted cardiac evaluation in a single study, reducing cost, lead time to diagnosis, and procedural adverse events while still providing supreme accuracy. As the stream of science and clinical practice worldwide emphasizes personalized and high-value care, noninvasive imaging has emerged as a new standard to prevent, diagnose, and guide the treatment of cardiac disease, reserving invasive procedures to cases where an intervention is required.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0053

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Joshua Latner, Ahmad N. Nusairat and Mustafa A. Abuelsamen et al. Multimodality Imaging for Cardiomyopathies in the Era of Precision Medicine. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0053

Loading

Sex Differences in Quality of Life and Clinical Outcomes in Patients with Heart Failure

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  Heart failure (HF) is generally associated with poor quality of life (QoL). Limited data are available characterizing health-related QoL (HRQL) in Chinese patients with HF.

The authors of this article used the Minnesota Living with Heart Failure Questionnaire (MLHFQ) to record QoL in 4082 patients with HF from China who were followed up over 12 months in the Heart Failure Registry of Patient Outcomes (HERO) study. Baseline HRQL and differences in QoL between women and men with heart failure were compared. Multivariable Cox regression with adjustment for variables was used to assess the association between MLHFQ summary

At baseline, the mean MLHFQ in the overall population was 42.9 ± 19.57; the scores for physical and emotional domains were 22.0 ± 8.69 and 8.66 ± 6.08, respectively. Women had a higher (poorer) MLHFQ summary score (44.27 ± 19.13) than men (41.63 ± 19.90) (P<0.001). Female patients also had higher MLHFQ physical and emotional scores than male patients (P<0.001). The specific scores of the questionnaire were higher in women than men. NYHA class was the strongest independent predictor of MLHFQ score (β=6.12 unit increment; P<0.001). Sex was not independently associated with higher MLHFQ scores after multivariable adjustments. The 12-month mortality in the overall cohort was 19.6%, the hospitalization rate was 24.4%, and the composite endpoint was 40.15%. A 10-point increase in MLHFQ score was associated with higher risk of mortality (female and male HRs=1.19 [95% CI 1.12–1.26]; P<0.001 and 1.18 [95% CI 1.12–1.24]; P<0.001, respectively) and composite outcomes (HRs=1.08 [95% CI 1.04–1.13]; P<0.001 and 1.11 [95% CI 1.07–1.14]; P<0.001, respectively). Females did not show a significant association between HRQL and hospitalization (HR=1.04 [95% CI 0.99–1.09]; P=0.107).

Quality of life was largely poorer in women than men, but was similar between sexes in terms of physical burden and emotional limitation. HRQL is an independent predictor of all-cause death and HF hospitalization in patients with HF.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0046

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Liu Jingxuan, Zhou Lu and Wang Xuesi et al. Sex Differences in Quality of Life and Clinical Outcomes in Patients with Heart Failure. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0046

Loading

Combination of Neutrophil Count and Gensini Score as a Prognostic Marker in Patients with Acute Coronary Syndrome and Uncontrolled Type 2 Diabetes Mellitus Undergoing Percutaneous Coronary Intervention

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Several biomarkers have been studied as prognostic indicators among people with diabetes and coronary artery disease (CAD). The purpose of this study was to determine the prognostic value of neutrophil counts and the Gensini score in patients with type 2 diabetes (T2DM) and Acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).

A total of 694 people with ACS and T2DM who simultaneously had elevated HBA1c received PCI. Spearman rank correlation estimates were used for correlation evaluation. Multivariate Cox regression and Kaplan-Meier analysis were used to identify characteristics associated with major adverse cardiovascular and cerebrovascular events (MACCEs) and patient survival. The effects of single- and multi-factor indices on MACCEs were evaluated through receiver operating characteristic curve analysis.

The Gensini score and neutrophil count significantly differed between the MACCE and non-MACCE groups among patients receiving PCI who had concomitant ACS and T2DM with elevated HBA1c (P<0.001). The Gensini score and neutrophil count were strongly associated with MACCEs (log-rank, P<0.001). The Gensini score and neutrophil count, alone or in combination, were predictors of MACCEs, according to multivariate Cox regression analysis (adjusted hazard ratio [HR], 1.005; 95% confidence interval [CI], 1.002–1.008; P=0.002; adjusted HR, 1.512; 95% CI, 1.005–2.274; P=0.047, respectively). The Gensini score was strongly associated with neutrophil count (variance inflation factor ≥ 5). Area under the curve analysis revealed that the combination of multivariate factors predicted the occurrence of MACCEs better than any single variable.

In patients with T2DM and ACS with elevated HBA1c who underwent PCI, both the Gensini score and neutrophil count were independent predictors of outcomes. The combination of both predictors has a higher predictability.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0051

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Yanyan Xu, Zhen Qin and Jiamin Gao et al. Combination of Neutrophil Count and Gensini Score as a Prognostic Marker in Patients with ACS and Uncontrolled T2DM Undergoing PCI. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0051

Loading

It’s Time to Consider Ablation as First-Line Therapy for Atrial Fibrillation

Announcing a new article publication for Cardiovascular Innovations and Applications journal.   Atrial fibrillation is the most common arrhythmia worldwide, affecting millions of the general population. It is a leading cause of stroke and is associated with many other long-term adverse cardiovascular issues. Long-term management of atrial fibrillation can involve simply controlling the ventricular rate with AV nodal blocking agents (rate control strategy) versus restoring and maintaining sinus rhythm (rhythm control strategy). For many years, pharmacologic rate control or rhythm control were both considered acceptable first-line therapeutic strategies. More recently, however, catheter ablation has emerged as a viable and potentially more effective treatment option than drug therapy, especially in patients with heart failure. Given the increasing efficacy and safety of ablation, practice is evolving toward ablation being considered first-line therapy for more patients. Indeed, both the 2014 AHA/ACC/HRS guidelines and the 2020 ESC guidelines for management of atrial fibrillation state that ablation can be considered as a first-line approach in patients with either symptomatic paroxysmal or persistent atrial fibrillation. In this article the authors discuss evidence supporting catheter ablation as first-line therapy for atrial fibrillation.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0052

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Steven Ross and William Miles. It’s Time to Consider Ablation as First-Line Therapy for Atrial Fibrillation. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0052

Loading